US › Healthcare

Neuphoria Therapeutics Inc (NEUP)

US · Healthcare · Biotechnology

$3.30-0.30%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.2M

Net profit

$-4.9M

EPS

$-0.13

EPS estimate

$-0.56

Net margin

-417.7%

EPS came in at -0.13 against a street estimate of -0.56 — a beat of 76.8%.

Key statistics

Market cap

$18.3M

Forward P/E

0.0

P/B

0.81

Book value

$4.55

EPS (TTM)

$-3.06

52-week high

$17.19

52-week low

$3.19

50-day MA

$3.73

200-day MA

$4.21

Analyst view

Analysts rate Neuphoria Therapeutics Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $7.00.

Shareholding

Insiders

5.02%

Institutions

43.34%

Largest institutional holders

Fund	Stake
Lynx1 Capital Management, LP	16.18%
AdvisorShares Investments, LLC	4.67%
Vanguard Capital Management, LLC	3.21%
Shay Capital LLC	2.88%
Balyasny Asset Management LLC	2.63%
Citadel Advisors Llc	1.34%
Geode Capital Management, LLC	0.92%
Ikarian Capital, LLC	0.88%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neuphoria Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.